103 related articles for article (PubMed ID: 21207420)
1. Regulatory BCL2 promoter polymorphism (-938C>A) is associated with adverse outcome in patients with prostate carcinoma.
Bachmann HS; Heukamp LC; Schmitz KJ; Hilburn CF; Kahl P; Buettner R; Nückel H; Eisenhardt A; Rübben H; Schmid KW; Siffert W; Eggert A; Schramm A; Schulte JH
Int J Cancer; 2011 Nov; 129(10):2390-9. PubMed ID: 21207420
[TBL] [Abstract][Full Text] [Related]
2. The AA genotype of the regulatory BCL2 promoter polymorphism ( 938C>A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients.
Bachmann HS; Otterbach F; Callies R; Nückel H; Bau M; Schmid KW; Siffert W; Kimmig R
Clin Cancer Res; 2007 Oct; 13(19):5790-7. PubMed ID: 17908970
[TBL] [Abstract][Full Text] [Related]
3. The bcl2 -938CC genotype has poor prognosis and lower survival in renal cancer.
Hirata H; Hinoda Y; Nakajima K; Kikuno N; Suehiro Y; Tabatabai ZL; Ishii N; Dahiya R
J Urol; 2009 Aug; 182(2):721-7. PubMed ID: 19539330
[TBL] [Abstract][Full Text] [Related]
4. Association of the CC genotype of the regulatory BCL2 promoter polymorphism (-938C>A) with better 2-year survival in patients with glioblastoma multiforme.
El Hindy N; Bachmann HS; Lambertz N; Adamzik M; Nückel H; Worm K; Zhu Y; Sure U; Siffert W; Sandalcioglu IE
J Neurosurg; 2011 Jun; 114(6):1631-9. PubMed ID: 21250804
[TBL] [Abstract][Full Text] [Related]
5. The regulatory BCL2 promoter polymorphism (-938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma.
Lehnerdt GF; Franz P; Bankfalvi A; Grehl S; Kelava A; Nückel H; Lang S; Schmid KW; Siffert W; Bachmann HS
Ann Oncol; 2009 Jun; 20(6):1094-9. PubMed ID: 19196738
[TBL] [Abstract][Full Text] [Related]
6. BCL2 genotypes and prostate cancer survival.
Renner W; Langsenlehner U; Krenn-Pilko S; Eder P; Langsenlehner T
Strahlenther Onkol; 2017 Jun; 193(6):466-471. PubMed ID: 28396899
[TBL] [Abstract][Full Text] [Related]
7. Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia.
Nückel H; Frey UH; Bau M; Sellmann L; Stanelle J; Dürig J; Jöckel KH; Dührsen U; Siffert W
Blood; 2007 Jan; 109(1):290-7. PubMed ID: 16960146
[TBL] [Abstract][Full Text] [Related]
8. ATM, BCL2, and TGFβ Gene Polymorphisms as Radiotherapy Outcome Biomarkers in Head and Neck Squamous Cell Carcinoma Patients.
Agostini LP; Stur E; Garcia FM; Ventorim DP; Dos Reis RS; Dettogni RS; Dos Santos EVW; Peterle GT; Maia LL; Mendes SO; de Carvalho MB; Tajara EH; de Paula F; Dos Santos M; da Silva AMA; Louro ID
Genet Test Mol Biomarkers; 2017 Dec; 21(12):727-735. PubMed ID: 29135311
[TBL] [Abstract][Full Text] [Related]
9. Influence of BCL2-938C>A and BAX-248G>A promoter polymorphisms in the development of AML: case-control study from South India.
Cingeetham A; Vuree S; Dunna NR; Gorre M; Nanchari SR; Edathara PM; Meka P; Annamaneni S; Digumarthi R; Sinha S; Satti V
Tumour Biol; 2015 Sep; 36(10):7967-76. PubMed ID: 25957891
[TBL] [Abstract][Full Text] [Related]
10. Influence of BCL2-938 C>A promoter polymorphism and BCL2 gene expression on the progression of breast cancer.
Bhushann Meka P; Jarjapu S; Vishwakarma SK; Nanchari SR; Cingeetham A; Annamaneni S; Mukta S; Triveni B; Satti V
Tumour Biol; 2016 May; 37(5):6905-12. PubMed ID: 26662799
[TBL] [Abstract][Full Text] [Related]
11. Association of the AA genotype of the BCL2 (-938C>A) promoter polymorphism with better survival in ovarian cancer.
Heubner M; Wimberger P; Otterbach F; Kasimir-Bauer S; Siffert W; Kimmig R; Nückel H
Int J Biol Markers; 2009; 24(4):223-9. PubMed ID: 20082279
[TBL] [Abstract][Full Text] [Related]
12. Bcl2 -938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy.
Hirata H; Hinoda Y; Kikuno N; Suehiro Y; Shahryari V; Ahmad AE; Tabatabai ZL; Igawa M; Dahiya R
J Urol; 2009 Apr; 181(4):1907-12. PubMed ID: 19237173
[TBL] [Abstract][Full Text] [Related]
13. Prognostic assessment of three single-nucleotide polymorphisms (GNB3 825C>T, BCL2-938C>A, MCL1-386C>G) in extrahepatic cholangiocarcinoma.
Fingas CD; Katsounas A; Kahraman A; Siffert W; Jochum C; Gerken G; Nückel H; Canbay A
Cancer Invest; 2010 Jun; 28(5):472-8. PubMed ID: 19968497
[TBL] [Abstract][Full Text] [Related]
14. Association of BCL2-938C>A genetic polymorphism with glioma risk in Chinese Han population.
Li W; Qian C; Wang L; Teng H; Zhang L
Tumour Biol; 2014 Mar; 35(3):2259-64. PubMed ID: 24287948
[TBL] [Abstract][Full Text] [Related]
15. Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck.
Chen K; Hu Z; Wang LE; Sturgis EM; El-Naggar AK; Zhang W; Wei Q
Carcinogenesis; 2007 Sep; 28(9):2008-12. PubMed ID: 17693666
[TBL] [Abstract][Full Text] [Related]
16. Impact of BCL2 polymorphisms on survival in transitional cell carcinoma of the bladder.
Hess J; Stelmach P; Eisenhardt A; Rübben H; Reis H; Schmid KW; Bachmann HS
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1659-1670. PubMed ID: 28417194
[TBL] [Abstract][Full Text] [Related]
17. Polymorphism in apoptotic BAX (-248G>A) gene but not in anti-apoptotic BCL2 (-938C>A) gene and its protein and mRNA expression are associated with cervical intraepithelial neoplasia.
Fernandes AT; Rocha NP; Vendrame E; Russomano F; Grinsztejn BJ; Friedman RK; Pinto AC; Klumb EM; Avvad E; Macedo J; Martínez-Maza O; Bonecini-Almeida Mda G
Apoptosis; 2015 Oct; 20(10):1347-57. PubMed ID: 26272263
[TBL] [Abstract][Full Text] [Related]
18. The BCL2 -938C>A Promoter Polymorphism Is Associated with Risk for and Time to Aseptic Loosening of Total Hip Arthroplasty.
Stelmach P; Wedemeyer C; Fuest L; Kurscheid G; Gehrke T; Klenke S; Jäger M; Kauther MD; Bachmann HS
PLoS One; 2016; 11(2):e0149528. PubMed ID: 26881923
[TBL] [Abstract][Full Text] [Related]
19. Effect of the BCL2 gene polymorphism on survival in advanced-stage non-small cell lung cancer patients who received chemotherapy.
Masago K; Togashi Y; Fujita S; Nagai H; Sakamori Y; Okuda C; Kim YH; Mishima M
Oncology; 2013; 84(4):214-8. PubMed ID: 23364242
[TBL] [Abstract][Full Text] [Related]
20. The BCL-2 promoter (-938C>A) polymorphism does not predict clinical outcome in chronic lymphocytic leukemia.
Kaderi MA; Norberg M; Murray F; Merup M; Sundström C; Roos G; Aleskog A; Karlsson K; Axelsson T; Tobin G; Rosenquist R
Leukemia; 2008 Feb; 22(2):339-43. PubMed ID: 18046447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
